Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Abpro Holdings ( (ABP) ) just unveiled an update.
On January 17, 2026, Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its CEO and chairman, Miles J.W. Suk, to finance the premium for its directors’ and officers’ liability insurance, with the funds paid directly to the insurer or broker, no interest charged for the first three months, and thereafter accruing at a variable rate tied to three‑month Term SOFR plus 2.0% until the nine‑month maturity. On January 16, 2026, director Ian McDonald resigned from the board and all its committees without any dispute with the company, and the board appointed pharmaceutical industry veteran Dr. Byung‑Hak Yoon to fill the resulting Class I directorship and committee vacancies, signaling continuity in governance and reinforcing the company’s industry expertise at the board level.
The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.
More about Abpro Holdings
Abpro Holdings, Inc. operates in the broader life sciences and pharmaceutical ecosystem, with board representation drawn from biotechnology, medical devices and pharma-focused leadership, indicating a strategic focus on biopharma and related health industries.
Average Trading Volume: 81,755
Technical Sentiment Signal: Sell
Current Market Cap: $8.39M
For detailed information about ABP stock, go to TipRanks’ Stock Analysis page.